Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:11 PM ET


Company Overview of Dr. Reddy's Laboratories Ltd.

Company Overview

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordanc...

8-2-337, Road No. 3

Banjara Hills

Hyderabad,  500034


Founded in 1984

20,373 Employees


91 40 4900 2900


91 40 4900 2999

Key Executives for Dr. Reddy's Laboratories Ltd.

Co-Chairman, Chief Executive Officer, Managing Director, Member of the Management Council, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Age: 55
Total Annual Compensation: $6.3M
Chairman of The Board, Member of The Management Council, Chairman of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Age: 48
Total Annual Compensation: $6.3M
Compensation as of Fiscal Year 2015.

Dr. Reddy's Laboratories Ltd. Key Developments

Drug makers Reportedly Seeks Acquisition Of Products To Be Hived Off Teva Pharmaceutical

Drug makers reportedly are seeking acquisition of tens of products to be hived off in the US by Teva Pharmaceutical Industries Limited (NYSE:TEVA). Cipla Limited (NSEI:CIPLA) and Glenmark Pharmaceuticals Ltd. (BSE:532296) are among some 30 companies bidding for tens of products to be hived off in the US, the world's biggest pharma market, as part of Teva Pharmaceutical Industries's acquisition of Allergan plc (NYSE:AGN)'s generics business. Industry sources indicated to ET that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 million. By regulations of the US Federal Trade Commission, Teva Pharmaceutical Industries needs to undergo a divestiture process for the overlapping products as part of its deal to ensure fair market competition. "In the second round about 20 companies are expected to figure and the actual valuations of the bids will be known during that process," one industry source said. While it could not be confirmed immediately, Cadila Healthcare Limited (BSE:532321) and Dr. Reddy's Laboratories Ltd. (BSE:500124)'s may also form part of the list that made it to the second round. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. "As a pharmaceutical company we are constantly in discussions with multiple parties on potential collaboration opportunities - in line with our aspiration to drive access and ensure availability of high quality, affordable medicines," the person said. Glenmark too declined to comments.

Dr. Reddy's Laboratories Ltd. - Special Call

To clarify investors’ queries on the warning letter issued by the US FDA dated November 05, 2015

Biocodex Signs Distribution Agreement with Dr. Reddy’s to Market Products in Romania

Dr. Reddy's Laboratories has entered into a strategic alliance with Biocodex to market and distribute Biocodex products in the Romanian market. Biocodex has announced the change in partnership and effective October 01, 2015, Dr. Reddy's has been given the complete rights for promotion and distribution of the Biocodex products across Romania.

Recent Private Companies Transactions

September 25, 2015
Alchemia Limited, Worldwide Exclusive Intellectual Property Rights of Fondaparinux Sodium
April 1, 2015
UCB India Private Limited, Portfolio of Established Product Business

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Dr. Reddys Laboratories Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at